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Abstract 
Background 
Trimethylation of histone H3 lysine 4 (H3K4me3) accumulates at promoters in a gene 
activity dependent manner. The Set1 complex is responsible for most H3K4me3 in somatic 
cells and contains the conserved subunit Cfp1, which is implicated in targeting the Set1 
complex to CpG islands in mammals. In mouse embryonic stem cells, Cfp1 is necessary for 
H3K4me3 accumulation at constitutively active gene promoters, but is not required to 
maintain steady-state transcription of the associated gene. 
Results 
Here we show that Cfp1 is instrumental for targeting H3K4me3 to promoters upon rapid 
transcriptional induction in response to external stimuli. Surprisingly, H3K4me3 
accumulation is not required to ensure appropriate transcriptional output but rather plays gene 
specific roles. We also show that Cfp1-dependent H3K4me3 deposition contributes to H3K9 
acetylation genome wide, suggesting that Cfp1 dependent H3K4me3 regulates overall H3K9 
acetylation dynamics and is necessary for histone acetyl transferase recruitment. Finally, we 
observe increased antisense transcription at the start and end of genes that require Cfp1 for 
accurate deposition of H3K4me3 and H3K9ac. 
Conclusions 
Our results assign a key role for Cfp1 in establishing a complex active promoter chromatin 
state and shed light on how chromatin signaling pathways provide context-dependent 
transcriptional outcomes. 
Background 
In eukaryotes, specialised chromatin structures contribute to multiple DNA-related processes 
including transcription, replication and repair. Combinations of specific histone post-
translational modifications correlate well with the functional status of the underlying DNA 
sequence, for example at sites of transcriptional initiation, elongation or at distal regulatory 
elements [1–4]. Transitions between chromatin states accompany differentiation, cellular 
reprogramming, and disease processes [2,4]. However, it is unclear whether histone 
modifications patterns are set up as a consequence of ongoing dynamic processes such as 
transcription or if they perform instructive roles. It is therefore crucial to systematically 
address the role of individual histone modifications in different contexts. As chromatin marks 
usually arise in reproducible groups comprising the same set of modifications, it is important 
to decipher their interdependence to help determine the biological significance of complex, 
potentially redundant, chromatin states. 
H3K4me3 is a mark associated with eukaryotic gene promoters. In yeast, it is a feature of 
actively expressed genes [5,6], suggesting that it positively influences transcription. In 
mammals, H3K4me3 is found at active and inactive promoters at a level dependent on gene 
activity [7,8]. Most promoters in mouse and human are associated with CpG islands (CGI), 
which are DNA elements showing high G + C and CpG content that are usually free of DNA 
methylation [9,10]. CGIs possess a characteristic chromatin structure thought to predispose 
them towards promoter activity [9,11]. For example, CpG islands can directly recruits 
H3K4me3, favouring transcriptional competence [12]. In mammalian stem cells, H3K4me3 
is found together with H3K27me3 at bivalently marked CpG islands promoters [13,14], 
which are poised for activation by developmental signals upon lineage commitment. 
H3K4 methylation is achieved by conserved enzymatic complexes related to the yeast 
COMPASS (Complex Associated with Set1) [15,16]. Mammalian COMPASS complexes 
vary in their catalytic component (Setd1A-B, Mll1-4) as well as in specific subunits that 
contribute to their functional diversity (Reviewed in [17]). Set1-containing COMPASS is the 
main H3K4 histone methyltransferase in most organisms [18–21]. Mll1/Mll2 COMPASS-like 
have gene specific roles in H3K4me3 deposition [22–24], while Mll3/Mll4 COMPASS-like 
complexes mainly contribute to H3K4me1 at enhancers [25,26]. 
CxxC finger protein 1 (Cfp1, CXXC1 or CGBP) is a specific component of Set1-containing 
complexes [17,27]. Cfp1 binds unmethylated CpGs and targets Set1 and H3K4me3 to most 
CpG islands in somatic cells, regardless of their transcriptional activity [12]. In embryonic 
stem cells, Cfp1 plays a fundamental role in genome wide H3K4me3 organisation [28]. It is 
required for strong H3K4me3 enrichment at constitutively active gene promoters, but plays 
little role in depositing this mark at poised gene, including bivalent promoters [28]. 
Surprisingly, in stem cells, reduced H3K4me3 deposition at active promoters does not 
drastically affect steady-state transcription [28,29]. On the other hand, loss of the Cfp1 gene 
in mice results in early embryonic lethality [30] and Cfp1-deficiency in somatic cell lines is 
toxic [12,31]. Thus, it is possible that Cfp1-deficiency impairs the proper induction of 
transcription programs in response to differentiation signals or to external stimuli like stress, 
potentially explaining why Cfp1
-/-
 ES cells are unable to differentiate in vitro [32]. 
  
In this study, we ask how Cfp1 affects H3K4me3 dynamics in rapid, regulated gene 
expression, using the transcriptional response to DNA damage as model. We show that in 
addition to its role in regulating steady-state H3K4me3 deposition in ES cells, Cfp1 is 
instrumental in targeting this modification to gene promoters upon rapid transcriptional 
induction. We also observe that the Cfp1-dependent H3K4me3 accumulation that follows 
gene induction is not strictly required to ensure appropriate transcriptional output but rather 
plays gene-specific roles. We also identify a strong co-dependency between H3K4me3 and 
H3K9ac deposition upon transcriptional induction as well as in normally cycling ES cells. 
Our results suggest that Cfp1-dependent H3K4me3 regulates overall H3K9 acetylation 
dynamics and is necessary for histone acetyl transferase (HAT) recruitment. Finally, we 
describe elevated antisense transcription at the start and end of those genes that requires Cfp1 
for accurate H3K4me3 and H3K9ac deposition. 
Results 
Cfp1 is required for H3K4me3 deposition following transcriptional induction 
To determine the role of Cfp1 in H3K4me3 deposition upon rapid transcriptional activation, 
we analysed the transcriptional response to doxorubicin, a DNA damaging agent that triggers 
sudden p53-dependent gene expression changes in mouse ES cells [29,33,34]. Doxorubicin 
treatment (1 μM, 6 hours) in wt ES cells rapidly caused increased binding of phosphorylated 
p53 (Serine 18 in mouse) at the Cdkn1a (p21) locus, leading to a robust induction of the 
Cdkn1a gene (Additional file 1: Figure S1A, S1B, S1C). This was accompanied by increased 
H3K4me3 levels at the Cdkn1a locus (Additional file 1: Figure S1D) as previously described 
[29]. To identify genes whose expression is regulated in response to doxorubicin treatment, 
we performed RNA-Seq experiments using cDNA libraries from ribosomal RNA-depleted 
total RNA in doxorubicin-treated and untreated wt ES cells. We identified 1264 genes that 
significantly changed expression upon doxorubicin treatment (p-value < 0.05, fold change 
≥2.5) comprising 775 upregulated and 489 downregulated genes (Figure 1A, Additional file 
2). The list included many genes previously implicated in the p53-dependent transcriptional 
response to doxorubicin [33,34] in both the upregulated (Wnt9, Wnt3, Btg2, Cdkn1a, Mdm2, 
Bbc3) and downregulated (Sox2, Esrrb, Sall4, Zic3, n-Myc, Nanog) gene sets (Figure 1A, 1B, 
Additional file 3: Figure S2A). These data confirm the validity of our data analysis pipeline. 
Figure 1 Cfp1 is crucial for H3K4me3 deposition at promoters of genes regulated upon 
DNA damage. (A) Heatmap representing gene expression changes induced by doxorubicin 
treatment (p-value < 0.05, fold change ≥ 2.5). Genes highlighted were identified in previous 
studies [33,34]. (B) Genome browser screenshots representing RNA-Seq normalised read 
count in wt ES cells at the Cdkn1a locus. Position for qPCR primers used along the study is 
also represented. (C) Heatmap showing H3K4me3 normalised read count 3 kb upstream and 
downstream of TSS of genes induced by doxorubicin wt ES cells (n = 755). Unmethylated 
CpGs are represented by CAP-Seq enrichment in wt ES cells [28]. (D) ChIP-qPCR analysis 
of H3K4me3 enrichment at the Cdkn1a locus for untreated or doxorubicin treated wt and 
Cfp1
-/-
 ES cells. Results are expressed as fold enrichment relative to input DNA and a control 
intergenic region on chromosome 15. Control corresponds to an intergenic region on 
chromosome 5. Gapdh and Actb promoters are also shown. Data are represented as mean ± 
SD, n = 3. P-values were calculated using two-tailed Student’s t tests (*) p < 0.05, (**) p < 
0.01, (ns) p > 0.05. (E) Same as (C) for Cfp1
-/-
 ES. (F) Genome browser screenshots 
representing H3K4me3 ChIP-Seq normalised read count in wt (untreated in blue, treated in 
black) and Cfp1
-/-
 (untreated in pink, treated in red) ES cells at the Cdkn1a locus. (G) 
Average profile showing H3K4me3 normalised read count at TSS of genes induced by 
doxorubicin treatment in wt ES cells. Input DNA is shown as a control. Signal is displayed 
from -3 kb to +3 kb surrounding each annotated TSS. (H) Comparison of H3K4me3 
normalised read density at TSS of upregulated genes, from 3 kb upstream to 3 kb 
downstream. P-values were calculated using two-tailed unpaired Wilcoxon tests, (*) p < 0.05, 
(**) p < 0.01, (***) p < 0.001, (****) p < 0.0001. 
H3K4me3 associates with active or poised promoters at a level dependent on gene activity 
[7,8]. Furthermore, transcriptional induction can lead to increased H3K4me3 at the activated 
gene promoter [35]. We asked how expression changes induced by doxorubicin affect 
H3K4me3 patterns at cognate promoters by performing H3K4me3 chromatin 
immunoprecipitation coupled to massively parallel DNA sequencing (ChIP-Seq) in wt ES 
cells that were untreated or treated with doxorubicin. Most promoters of upregulated genes 
are CpG-rich and displayed H3K4me3 enrichment before induction (Figure 1C), which is 
compatible with the notion that they are poised for rapid activation in response to external 
stimuli [36]. As expected, transcriptional induction by doxorubicin led to increased 
H3K4me3 levels at those promoters (Figure 1C). On the other hand, genes downregulated by 
doxorubicin treatment were characterised by decreased H3K4me3 (Additional file 3: Figure 
S2A, S2B), emphasizing the correlation between H3K4me3 and transcriptional activity. 
In ES cells, Cfp1 plays a key role in establishing H3K4me3 at constitutively active loci, 
while its general contribution to H3K4me3 deposition at poised genes is minimal [28]. To 
explore how Cfp1 contributes to H3K4me3 dynamics in regulated gene expression, we 
analysed H3K4me3 status at the Cdkn1a locus in response to doxorubicin in Cfp1
-/-
 ES cells 
by ChIP-qPCR (Figure 1D). While we observed a robust increase in H3K4me3 at TSS1, 
TSS2 and intron 1 upon doxorubicin treatment in wt ES cells, it was apparent that Cfp1-
deficiency led to severe defect in H3K4me3 accumulation at the Cdkn1a locus (Figure 1D). 
ChIP-qPCR using an antibody recognising total histone H3 and a control IgG confirmed the 
specificity of this result (Additional file 1: Figure S1E and S1F). As expected, Cfp1-
deficiency also led to decreased H3K4me3 near the TSS of constitutively active Actb and 
Gapdh gene loci (Figure 1D). We extended the analysis by performing H3K4me3 ChIP-Seq 
analyses in Cfp1
-/-
 ES cells treated or not with doxorubicin. Indeed, H3K4me3 did not 
increase at promoters of genes normally upregulated by doxorubicin treatment, but instead 
remained at basal levels in both untreated or doxorubicin treated Cfp1
-/-
 ES cells (Figure 1E, 
1F, 1G, 1H). This establishes that Cfp1 is instrumental in H3K4me3 deposition in response to 
an external stimulus in ES cells. On the other hand, genes downregulated by doxorubicin 
showed reduced H3K4me3 in untreated Cfp1
-/-
 compared to untreated wt ES cells and these 
levels did not drastically change upon doxorubicin treatment (Additional file 3: Figure S2B, 
S2C, S2D, S2E and S2F). Down-regulated genes are highly expressed in untreated ES cells 
(Additional file 3: Figure S2G) and therefore require Cfp1 for accurate H3K4me3 deposition 
at their promoters in normally proliferating mouse ES cells [28]. We conclude that upon 
transcriptional activation, H3K4me3 levels are enhanced at induced promoters in a Cfp1-
dependent manner. Thus Cfp1 not only plays a key role in determining proper H3K4me3 
patterns in normally proliferating ES cells [28], but is also instrumental in targeting this 
modification to gene promoters upon transcriptional induction in response to external stimuli. 
These findings favour a model whereby the Cfp1/Set1-containing complex acts mainly 
downstream of transcriptional activation. 
Low H3K4me3 at promoters only mildly affect transcriptional induction 
output 
Previous work established that lack of Cfp1-dependent H3K4me3 at constitutively active 
gene promoters does not drastically alter steady-state transcription in ES cells [28]. However, 
H3K4me3 mediated recruitment of Taf3 is reported to be crucial for transcriptional induction 
upon doxorubicin treatment in HCT116 cells [37]. We therefore tested whether altered 
H3K4me3 patterns affect the transcriptional response to doxorubicin. First, we checked that 
early response to doxorubicin was intact in Cfp1
-/-
 ES cells by confirming that p53 
stabilisation, phosphorylation and binding to the Cdnkn1a locus was indistinguishable 
between wt and Cfp1
-/-
 ES cells (Additional file 4: Figure S3A, S3B). We then performed 
RNA-Seq experiments in Cfp1
-/-
 ES cells treated or untreated with doxorubicin and looked 
for differential expression of genes that are inducible in wt ES cells. Many genes, including 
Mdm2, Btg2 and Wnt9a, were induced appropriately in the mutant cells (Additional file 4: 
Figure S3C). Others appeared to be affected in their transcriptional response, but this effect 
was generally mild and gene-dependent, with very few genes showing complete lack of 
activation or repression (Figure 2A, B and C). We also observe minor defects in genes 
repressed by doxorubicin (Figure 2A, 2B), but confirmed that Nanog responded properly in 
both treated wt and treated Cfp1
-/-
 ES cells (Figure 2D). To exclude the possibility that Cfp1 
deficiency affects global transcription in response to doxorubicin treatment, we performed 
absolute quantification RT-qPCR experiments. For this, we normalised transcript abundance 
to a spiked-in standard instead of an endogenous transcript (see Methods for details) as 
described in [38]. In this setting, we also observe efficient Cdkn1a and Mdm2 induction, as 
well as Nanog and Sox2 repression in doxorubicin treated wt and Cfp1
-/-
 ES cells (Figure 2E, 
F). Our results suggest that Cfp1 dependent H3K4me3 plays a minor role in insuring 
appropriate expression of inducible genes. The biological significance of modest deregulation 
at specific genes is however uncertain. 
Figure 2 Decreased H3K4me3 at regulated promoters mildly affects transcriptional 
output. (A) Heatmap comparing gene expression changes (as log2 fold change) induced by 
doxorubicin treatment in wt and Cfp1
-/-
 ES cells as determined by RNA-Seq. (B) Dot plot 
comparing gene expression differences in wt and Cfp1
-/-
 ES cells. Genes were sorted on the 
basis of their log2 fold change upon doxorubicin treatment in wt ES cells (most upregulated 
gene on the far left, most downregulated gene on the far right). The log2 fold changes (untr 
vs. Doxo) are plotted for wt (blue) and Cfp1
-/-
 ES cells (red). (C) Genome browser 
screenshots representing RNA-Seq signal (as normalised read count) in wt ES cells (untreated 
in blue, treated in black) and Cfp1
-/-
 (untreated in pink, treated in red) ES cells at the Cdkn1a 
locus. (D) Same as (C) for the Nanog locus. (E) Absolute quantification of Cdkn1a and 
Mdm2 mRNA levels in wt (untreated in blue, doxorubicin treated in black) and Cfp1
-/-
 ES 
cells (untreated in pink, doxorubicin treated in red) by RT-qPCR. Expression levels are 
normalised using an RNA spike-in standard (ERCC-00074) and then expressed as fold 
induction compared to the untreated value. The ERCC-00130 standard is shown as control. 
Data are represented as mean ± SD, n = 4. P-values were calculated using two-tailed 
Student’s t tests (*) p < 0.05, (**) p < 0.01, (ns) p > 0.05. (F) Same as (G) for Nanog, Sox2, 
Pou5f1, Gapdh, Actb mRNA levels. Lmna and ERCC-00096 are shown as control. 
Cfp1 is crucial for H3K9 acetylation at regulated promoters 
As lack of Cfp1 led to impaired H3K4me3 accumulation at doxorubicin-regulated promoters, 
we investigated whether other aspects of the chromatin landscape were also affected. Several 
reports have linked H3K4me3 levels at TSS with histone H3 acetylation [29,35,39,40]. Using 
an antibody directed against H3K9,K14ac, we observed increased histone acetylation at the 
Cdkn1a locus upon doxorubicin treatment in wt ES cells, but this effect was absent in Cfp1
-/-
 
cells (Figure 3A). A possible explanation is that histone H3 acetylation requires Cfp1-
dependent H3K4me3 deposition at the induced TSSs. This effect appears specific to 
H3K9,K14 as H3K27 acetylation levels were unaffected by absence of Cfp1 (Figure 3B). 
Furthermore, antibodies specifically directed against H3K9 or H3K14 acetylation revealed 
that Cfp1-deficiency more severely impacts H3K9 rather than H3K14 acetylation (Additional 
file 5: Figure S4A, S4B). To test whether Cfp1 dependent H3K4me3 at doxorubicin-
regulated promoters is generally associated with H3K9,K14 acetylation, we performed ChIP-
Seq experiments. In wt ES cells we observed increased histone TSS acetylation at genes 
induced by doxorubicin, but acetylation was severely reduced in Cfp1
-/-
 ES cells (Figure 3C, 
3E, Additional file 5: Figure S4C). At downregulated promoters, H3K9,K14 acetylation was 
decreased in treated wt ES cells, but its levels appear low in both untreated and doxorubicin 
treated Cfp1
-/-
 cells (Figure 3D, F, Additional file 5: Figure S4D). There is therefore a strong 
similarity between H3K4me3 and H3K9,K14ac patterns at doxorubicin-regulated promoters, 
as levels of both are directly related to transcriptional activity. Interestingly, lack of Cfp1 
impacts both modifications at this subset of genes, strongly suggesting co-dependency. 
Figure 3 Cfp1 is crucial for H3K9 acetylation at regulated promoters. (A) ChIP-qPCR 
analysis of H3K9,K14ac enrichment at the Cdkn1a locus for untreated (untr) or doxorubicin 
treated (Doxo) wt and Cfp1
-/-
 ES cells. Results are expressed as fold enrichment relative to 
input DNA and a control intergenic region on chromosome 15. Control corresponds to an 
intergenic region on chromosome 5. Data are represented as mean ± SD, n = 3. P-values were 
calculated using two-tailed Student’s t tests (*) p < 0.05, (**) p < 0.01, (ns) p > 0.05. (B) 
Same as (A) for H3K27ac enrichment. Data are represented as mean ± SD, untr n = 2, Doxo 
n = 4. (C) Heatmap representation showing H3K9,K14ac normalised read count 3 kb 
upstream and downstream of TSS of genes upregulated by doxorubicin treatment in wt ES 
cells (n = 755). (D) Same as (C) for downregulated genes (n = 489). (E) Genome browser 
screenshots representing H3K9,K14ac ChIP-Seq signal (as normalised read count) in wt 
(untreated in blue, treated in black) and Cfp1
-/-
 (untreated in pink, treated in red) ES cells at 
the Cdkn1a locus. (F) Same as (E) for the Nanog locus. (G) Same as (A) for Gcn5 
enrichment at the Cdkn1a locus. Data are represented as mean ± SD, n = 3. P-values were 
calculated using two-tailed Student’s t tests (*) p < 0.05, (**) p < 0.01, (ns) p > 0.05. (H) 
Same as (G) for Hdac1 enrichment at the Cdkn1a locus. Data are represented as mean ± SD, 
n = 3. P-values were calculated using two-tailed Student’s t tests (*) p < 0.05, (**) p < 0.01, 
(ns) p > 0.05. 
H3K4me3 can act as a binding platform that attracts histone acetyltransferase complexes. In 
particular, the Gcn5 containing SAGA complex can be targeted to H3K4me3 nucleosomes by 
the adaptor subunit Sgf29 [41]. Consistent with this model, we observed that decreased 
H3K4me3 at the Cdkn1a promoter is associated with decreased Gcn5 binding at the same 
genomic location (Figure 3G), which is likely to account for decreased H3K9 acetylation. 
Furthermore, we observed that reduced histone acetylation at the Cdkn1a locus in Cfp1
-/-
 ES 
cells was not due to increased binding of histone deacetylase 1 (Hdac1, Figure 3H). We 
conclude that H3K4me3 defects caused by Cfp1-deficiency at promoters affect overall H3K9 
acetylation dynamics, probably by directly impairing H3K4me3-mediated HAT recruitment. 
H3K9ac levels follow H3K4me3 at Cfp1 regulated regions independent of 
gene induction 
Cfp1 influences H3K4me3 deposition at many genomic locations spread throughout the 
mouse ES cell genome and particularly at active gene promoters [28]. We tested whether 
Cfp1-deficiency affects histone acetylation at non-doxorubicin-inducible promoters by 
examining H3K4me3 patterns at the most active genes in wt ES cells as identified in our 
RNA-Seq dataset (n = 2500, Additional file 6). The results confirm that lack of Cfp1 leads to 
severely reduced H3K4me3 levels, mainly located downstream from the TSS (Figure 4A, B, 
E) and that this is accompanied with a reduction in H3K9,K14ac as determined by ChIP-Seq 
(Figure 4A, B, E). Similar results were obtained for this gene set when comparing 
doxorubicin-treated wt and Cfp1
-/-
 ES cells (Additional file 7: Figure S5A, S5B and S5E). 
The findings further support a mechanistic link between Cfp1-dependent H3K4me3 and 
H3K9ac at TSS in normally cycling mouse ES cells. 
Figure 4 H3K9 acetylation is altered at Cfp1 regulated regions. (A) Heatmap showing 
H3K4me3 (yellow) or H3K9,K14ac (blue) normalised read count at TSS for the most active 
genes in wt ES cells (n = 2500). Signal is displayed from -3 kb to +3 kb surrounding each 
annotated TSS for untreated wt or Cfp1
-/-
 ES cells. (B) Average profile showing H3K4me3 or 
H3K9,K14ac normalised read count at TSS for the most active genes in wt ES cells (n = 
2500). Signal is displayed from -3 kb to +3 kb surrounding each annotated TSS for untreated 
wt or Cfp1
-/-
 ES cells. (C) Same as (A) for regions aberrantly accumulating H3K4me3 in 
absence of Cfp1 (n = 14208). Signal is displayed from -1.5 kb to +1.5 kb surrounding the 
centre of the peak for each region for untreated wt or Cfp1
-/-
 ES cells. (D) Average profile 
showing H3K4me3 or H3K9,K14ac normalised read count for regions aberrantly 
accumulating H3K4me3 in absence of Cfp1 (n = 14208). Signal is displayed from -1.5 kb to 
+1.5 kb surrounding the centre of the peak. Input DNA is plotted as a reference. (E) 
Comparison of H3K4me3 or H3K9,K14ac normalised read density at TSS of the most active 
genes (n = 2500), from 3 kb upstream to 3 kb downstream. Box plots show the central 50% of 
the data (filled box), the median (central bisecting line) and 1.5X the interquartile range 
(whiskers). P-values were calculated using two-tailed unpaired Wilcoxon tests, (*) p < 0.05, 
(**) p < 0.01, (***) p < 0.001, (****) p < 0.0001. (F) Same as (E) for H3K4me3 or 
H3K9,K14ac normalised read density at regions aberrantly accumulating H3K4me3 in 
absence of Cfp1 (n = 14208), from 1.5 kb upstream to 1.5 kb downstream. 
Absence of Cfp1 in mouse ES cells has been shown to cause aberrant accumulation of 
H3K4me3 at many non-promoter regions [28]. We tested the possibility that these ectopic 
sites of H3K4me3 accumulation are also associated with increased H3K9ac. For this, we 
compared H3K4me3 and H3K9,K14ac density in wt and Cfp1
-/-
 ES cells at those sites where 
H3K4me3 accumulates in the absence of Cfp1 (Additional file 8). The results confirmed that 
on average, increased H3K4me3 at those regions is matched by increased H3K9,K14ac levels 
(Figure 4C, D and F). Furthermore, it was obvious that regions that accumulated the most 
H3K4me3 in Cfp1
-/-
 ES cells also showed highest H3K9,K14ac enrichment (Figure 4C, D 
and F). Again, this was confirmed when comparing doxorubicin treated wt and Cfp1
-/-
 ES 
cells (Additional file 7: Figure S5C, S5D and S5F). Some of the regions that accumulate 
H3K4me3 in cells lacking Cfp1 correspond to sites occupied by Ctcf or Cohesin [28]. We 
therefore analysed both H3K4me3 and H3K9,K14ac distributions at selected binding sites for 
those two factors in wt and Cfp1
-/-
 ES cells [42] (Additional files 9 and 10). Lack of Cfp1 
leads to increased H3K4me3 and this is associated with an increase in H3K9,K14ac 
(Additional files 11: Figure S6 and S7 and 12). We conclude that the altered H3K4me3 
pattern observed in mouse ES cells in the absence of Cfp1 is accompanied by an alteration in 
H3K9ac deposition. This suggesting a mechanistic co-dependency for these two histones 
marks, both of which are consistently associated with transcriptional activity. 
Decreased H3K4me3 and H3K9ac impact transcriptional accuracy upon 
induction 
Given the subtle effect of altered promoter H3K4me3 and H3K9ac on the transcriptional 
output of inducible genes, we tested whether other aspects of gene expression are affected by 
the altered chromatin landscape. First we examined RNA processing, as H3K4me3 is 
proposed to facilitate splicing factor loading [43]. We compared splicing efficiency for the 
Cdkn1a transcript upon induction in wt and Cfp1
-/-
 ES cells. We detected neither 
accumulation of the unspliced pre-mRNA nor reduction in a particular splicing product when 
comparing doxorubicin-treated wt and Cfp1
-/-
 ES cells (Figure 5A, 5B). This agrees with 
previous observation that decreased H3K4me3 at constitutively active genes does not 
drastically alter splicing in normally cycling ES cells [28]. 
Figure 5 Decreased H3K4me3 and H3K9ac influence transcriptional accuracy upon 
induction. (A) Schematic representation of the qPCR strategy used to quantify various 
Cdkn1a mRNA splicing products. Total RNA is detected using primers on 3’UTR (shown in 
red). (B) RT-qPCR analysis of Cdkn1a splicing products. P-values were calculated using 
two-tailed Student’s t tests (*) p < 0.05, (**) p < 0.01, (ns) p > 0.05. (C) Average profile 
showing sense RNA-Seq normalised read count at TSS of genes induced by doxorubicin 
treatment in wt ES cells (n = 755). Signal is displayed from -3 kb to +3 kb surrounding each 
annotated transcription start site. (D) Same as (C) for antisense RNA-Seq normalised read 
count (Note that sense and antisense transcripts are plotted on a different scale). (E) Average 
profile showing sense RNA-Seq normalised read count at TES of genes induced by 
doxorubicin treatment in wt ES cells (n = 755). Signal is displayed from -3 kb to +3 kb 
surrounding each annotated transcription start site. (F) Same as (E) for antisense RNA-Seq 
normalised read count (Note that sense and antisense transcripts are plotted on a different 
scale). (G) Comparison of sense or antisense RNA-Seq normalised read density at TSS of 
upregulated genes (n = 755), from 3 kb upstream to 3 kb downstream, in wt or Cfp1
-/-
 ES 
cells, treated or not with doxorubicin as indicated. Box plots show the central 50% of the data 
(filled box), the median (central bisecting line) and 1.5X the interquartile range (whiskers). P-
values were calculated using two-tailed unpaired Wilcoxon tests, (*) p < 0.05, (**) p < 0.01, 
(***) p < 0.001, (****) p < 0.0001. (H) Same as (G) for TES of upregulated genes (n = 755). 
Antisense transcription is also a feature of gene expression thought to be affected by H3K4 
methylation [44–46]. Active mammalian transcription units produce small sense and 
antisense RNA molecules at their TSS and Transcription End Sites (TES) [47,48]. We 
investigated levels of these transcripts at genes regulated by doxorubicin in wt and Cfp1
-/-
 ES 
cells using strand specific RNA-Seq datasets. As expected, upon induction sense RNA 
accumulated both downstream of the TSS and upstream of the TES (Figure 5C, D, G and H) 
and profiles were strongly similar when comparing doxorubicin treated wt and Cfp1
-/-
 ES 
cells. Induced genes also displayed increased divergent antisense transcription at both TSS 
and TES, albeit at much lower abundance, but this was strikingly elevated in Cfp1
-/-
 ES cells 
(Figure 5C, D, G and H). The results suggest that Cpf1-dependent increases in H3K4me3 and 
H3K9ac can play a role in regulating TSS and TES-associated small RNA transcription upon 
gene induction. The effect is marginal or non significant at genes downregulated by 
doxorubicin (Additional file 13: Figure S8). We propose that Cfp1-dependent H3K4me3 and 
H3K9ac deposition contributes to accurate RNA production at start and end of genes upon 
transcriptional induction. 
Discussion 
Understanding H3K4me3 deposition at gene promoters 
Cfp1 is required for accurate H3K4me3 deposition at constitutively active gene promoters in 
mouse ES cells [28]. Here we show that Cfp1 also plays an important role in targeting this 
modification upon transcriptional induction. This favours a model in which the Cfp1/Set1 
complex acts mainly downstream of the transcriptional apparatus, similar to yeast [5,6,49]. 
The data suggest a scenario whereby high H3K4me3 levels at promoters of genes regulated 
by external stimuli result from a multistep process. In the unstimulated state H3K4me3 is low 
and the promoter is poised for activation. Cfp1 seems to play little role in this “priming” 
process. When transcription is induced, however, Cfp1 is instrumental in causing the striking 
increase in H3K4me3 levels at the TSS. Similarly, Cfp1 is dispensable for H3K4me3 at 
bivalent genes [28], which are kept silenced in ES cells but are thought to be poised for 
activation by developmental cues [13,14,50]. The histone methyl transferase Mll2 is largely 
responsible for H3K4me3 deposition at bivalent promoters [23]. Thus different H3K4 
methyl-transferases play distinct roles in shaping the chromatin landscape, suggesting that 
histone modification patterns are the results of an intricate network of enzymatic activities. 
Variation in these histone modifications may create alternative binding surfaces for potential 
histone tail readers, leading to context dependent outcomes. According to this scenario, 
histone modifications do not act as simple on/off switches, but instead create molecular 
signaling gradients, allowing for subtle regulation of particular genomic loci in various 
conditions. More quantitative measurements of chromatin features are needed to fully 
appreciate their complexity and relationship to cell commitment and disease. 
H3K4me3 and H3K9ac deposition are linked in mouse ES cells 
A striking finding from our study is that alterations in Cfp1-dependent H3K4me3 deposition 
are accompanied by parallel defects in H3K9ac deposition. This is true for regions that either 
lose or gain H3K4me3 in the absence of Cfp1. An attractive possibility is that H3K9 
acetylation is downstream of H3K4me3, and, together with previous reports, points to a 
molecular function for H3K4me3 in targeting H3K9 acetylation. H3K4me3 and H3K9ac 
coincide at many gene promoters [8,51–53], but we observe that these two marks are 
mechanistically co-dependent. H3K4me3 was suggested to facilitate H3K9 acetylation [40] 
and Sgf29, a subunit of the SAGA complex, can bind H3K4me3 and facilitate recruitment of 
the Gcn5 HAT [41]. Accordingly, we find that decreased H3K4me3 in Cfp1
-/-
 ES cells leads 
to reduced Gcn5 recruitment at the Cdkn1a promoter. Furthermore, aberrant H3K4me3 
accumulation at ectopic sites in the absence of Cfp1 coincides with enhanced H3K9ac 
deposition at the same loci. These findings do not favour of a hypothesis where Cfp1 
functions in an as yet uncharacterised HAT complex, but this possibility cannot be formally 
excluded. We favour a simpler model whereby Cfp1-dependent enhancement of H3K4me3 
levels at TSSs contributes to recruitment of HATs, which increase H3K9 acetylation. 
Interestingly, the inverse relationship, whereby acetylation of histone H3 targets the Set1 
complex to chromatin, has been observed biochemically, although the acetylation affects 
residues other than K9 [54]. Further studies of the functional interplay between histone marks 
will undoubtedly shed valuable light on the biological significance of histone modifications. 
H3K4me3 and H3K9ac function in a context dependent manner 
Reduced H3K4me3 at a TSS does not affect steady-state transcription in ES cells [28,29]. We 
now extend this observation and show that H3K4me3 is largely dispensable for regulated 
gene expression in this cell type. In vitro, H3K4me3 stimulates assembly of the pre-initiation 
complex as well as p53 and p300 dependent transcription [37,54]. Furthermore, Taf3, a TBP-
associated protein that can bind H3K4me3, selectively regulates a p53 target gene induced by 
doxorubicin in colon cancer cells [37]. On the other hand, depletion of Mll2 in ES cells, 
which is responsible for H3K4me3 deposition at bivalent genes, has little effect on their rapid 
transcriptional induction [23]. Cfp1/Set1 associates with most CpG island promoters in 
mouse brain and is required for regulated gene expression in colon cancer cells [12,54]. In 
pluripotent cells, however, Cfp1 is only necessary for H3K4me3 deposition at active genes 
and does not strongly affect either steady-state or regulated gene expression ([28] and this 
study). We conclude that the impact of H3K4me3 deposition on nucleosomes is highly 
context dependent and that this modification may play gene and/or cell type-specific roles. 
Our data also imply that high level H3K9 acetylation is not required for both steady-state and 
regulated gene expression in ES cells. The association between histone acetylation and active 
transcription is well established [55,56], but it has been reported that HDACs, which remove 
acetylation, are also enriched at active gene promoters [40]. It appears that two of the marks 
most prominently associated with transcriptional initiation are not necessary for either steady-
state or regulated gene expression in mouse ES cells. It is possible that their functional 
significance is gene-specific and/or context-dependent. Alternatively, there may be general 
functions for these marks that have so far escaped detection. In yeast, Set1 deletion has 
effects on regulating antisense transcription [44–46]. We observed aberrant antisense 
transcription at TSS and TES of genes induced by doxorubicin, suggesting that H3K4me3 
and/or H3K9ac can regulate complex aspects of mRNA biogenesis. These transcripts are low 
in abundance, however, and do not seem to critically influence mRNA levels. A second 
possibility is that H3K4me3 and/or H3K9ac are required to help resolve potentially toxic R-
loops that arise at transcriptionally active CpG rich promoters in mammals [57]. Thirdly, the 
presence of these marks may fine-tune RNA Pol II dynamics in ways that are not easily 
caught by genome wide studies, which provide only an averaged snapshot of the cell 
population. 
Our data could also fit with the idea that histone modifications mainly modulate nucleosome 
dynamics [58,59]. ES cells reportedly have an intrinsically accessible, dynamic chromatin 
structure, which is believed to contribute to their pluripotency [4,60]. Such an atypical 
structure could be robust enough to sustain key processes such as transcription, for which 
histone modification only acts redundantly. Upon lineage commitment, however, a more 
restricted chromatin state may be acquired [4] for which histone modification mediated 
processes become necessary. One also needs to stay open to the idea that histone marks 
strongly associated with promoters or coding regions can play roles outside transcription. For 
example, H3K4me3, together with insulator proteins, demarcates the border of physical 
domains and might thus be important for shaping the 3D organisation of the nucleus [61] and 
H3K36me3 has recently been implicated in regulation of DNA repair [62]. There is still 
much to understand regarding the role of chromatin in complex genome organisation and 
function. 
Conclusions 
In conclusion, we show that Cfp1 is required for H3K4me3 accumulation at promoters upon 
rapid transcriptional induction, linking chromatin structure and transcriptional activity. We 
also uncover a strong relationship between Cfp1 dependant H3K4me3 accumulation and 
accurate H3K9ac deposition. As defects in H3K4me3 and H3K9ac accumulation at 
promoters do not drastically alter steady-state or regulated expression of the associated gene, 
our results suggest that those two histone modifications function downstream of the 
transcriptional apparatus and could potentially regulate small RNA levels around 
transcription units boundaries. 
Methods 
ES cells culture 
ES cells were grown in gelatinized dishes in Glasgow MEM (Gibco) supplemented with 10% 
foetal bovine serum (Hyclone), 1× MEM nonessential amino acids, 1 mM sodium pyruvate, 
50 μM 2-mercaptoethanol (Gibco) and LIF. E14TG2a ES cells were used as wt ES and Cfp1-/- 
ES cells have been described [32]. Doxorubicin was purchased from Sigma and used at a 
final concentration of 1 μM for 6 hours. 
Chromatin Immunoprecipitation (ChIP) 
ES cells were crosslinked with 1% formaldehyde at room temperature for 10 min, followed 
by 5 min incubation with 125 mM glycine at room temperature. Cells were washed in PBS, 
flash frozen in liquid nitrogen and stored at –80°C prior to use. Cell pellets were thawed on 
ice, resuspended in lysis buffer 1 (50 mM Hepes KOH, pH 7.9, 140 mM NaCl, 1 mM EDTA, 
10% Glycerol, 0.5% NP-40, 0.25% Triton X-100) and incubated for 10 min on a rotator at 
4°C. Cells were washed in TE (10 mM Tris-HCl, pH 8, 1 mM EDTA). 
For histone modifications and RNA Pol II ChIP, cells were resuspended in TE containing 
0.5% SDS, incubated on ice for 10 min and sonicated using a Bioruptor (Diagenode) on High 
setting for 18 cycles of 30 sec (30 sec pause between pulses). The sonicated extract was 
centrifuged at 20000 g for 10 min at 4°C and the supernatant diluted 5 fold with ChIP 
dilution buffer (20 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA). 
For Gcn5, CBP, Hdac1 and p53S15P ChIP, cells were sonicated in 20 mM Tris-HCl, pH 8, 
150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.1% SDS for 60 cycles of 30 sec (30 sec 
pause between pulses). 
Sonicated chromatin was incubated overnight with the appropriate antibody and immune 
complexes were precipitated using protein A-Sepharose (GE Healthcare) pre-blocked with 
BSA and yeast tRNA, for 30 min at 4°C. Complexes were washed three times with 20 mM 
Tris-HCl, pH 8, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.1% SDS, once with 20 
mM Tris-HCl, pH 8, 500 mM NaCl, 1% Triton X-100, 1 mM EDTA, 0.1% SDS, and once 
with TE 1X. Bound complexes were eluted from the beads with TE containing 1% SDS by 
heating at 65°C for 1 hr. Samples were diluted to 0.5% SDS with TE, then RNase A and 
NaCl (final concentration 0.3 M) were added and samples incubated for 4 hr to overnight at 
65°C to reverse crosslinking. Samples were treated with proteinase K (100 μg/ml) for 1 to 2 
hr at 55°C, phenol extracted and ethanol precipitated. 
Strand-specific RNA-seq 
Cells were lysed in TRI reagent (Sigma). Total RNA was then extracted with chloroform, 
precipitated with isopropanol and DNAse treated (DNA-free, Ambion). Ribosomal RNA 
from 5 μg of total RNA was depleted using Ribo-Zero kit (Epicentre). Strand specific RNA-
Seq libraries were prepared using Script-Seq V2 RNA-Seq library preparation kit (Epicentre) 
according to manufacturer’s instructions. 
Preparation of ChIP DNA for Illumina Sequencing 
ChIP DNA were end repaired by incubation at 20°C for 30 min with 3 U of T4 DNA 
Polymerase (NEB), 10 U of Polynucleotide Kinase (NEB), 2 U DNA Polymerase I Large 
(Klenow) fragment (NEB), 1x T4 DNA ligase reaction buffer (NEB) and 400 nM dNTPs. 
The enzymes were then heat inactivated at 75°C for 20 min, after which the DNA was 
ethanol precipitated. A tail of 'A' bases was added to the 3’ ends of the DNA by incubation 
with 5 U Klenow Fragment (3’-5’ exo-; NEB), 200nM dATP and 1x buffer 2 (NEB) at 37°C 
for 30 min. The enzymes were heat inactivated and cleaned up as before . Barcoded Ilumina 
paired end adaptors were then ligated to the processed ChIP DNA by incubation with 300 U 
of T4 DNA ligase (NEB), 1x T4 DNA ligase buffer (NEB), 7.5% PEG-6000 and 2 pmol of 
annealed Illumina adaptors for 3 hr at room temperature. Ligated DNA was purified using 
MinElute PCR columns (Qiagen) and eluted in 10 μl water. 
Library Preparation and Illumina Sequencing 
Ligated DNA was amplified by 16-18 cycles of PCR with primers complementary to the 
adaptor sequences and Phusion 2x premix (Finnzymes). The DNA was purified using 
QIAquick PCR Purification columns (Qiagen). The purified DNA was captured on an 
Illumina flow cell for cluster generation. Libraries were sequenced using an Illumina HiSeq 
to generate paired end 75 bp reads. For ChIP-Seq, 6 samples were multiplexed. Paired-end 
sequence reads were demultiplexed and mapped to the mouse genome (NCBIm37) using 
BWA version 0.5.9-r16 [63]. Uniquely aligned reads were selected for further analysis and 
duplicate reads were removed for H3K9,K14ac ChIP-Seq samples (duplication was very low 
in H3K4me3 samples). For H3K4me3, sequencing from 2 biological replicates was combined 
in a single file. For RNA-Seq, 8 samples were multiplexed. Paired-end sequence reads were 
mapped to the mouse genome (NCBIm37) using STAR version 2.20c_r200 [64] to allow 
spliced alignments. Biological replicates (2 for each condition) were kept separate for 
differential expression analysis but were merged to generate average profiles. 
RNA expression analysis 
A GTF file containing ensEMBL mouse transcript information (release 67) was used to 
generate a count table with HTSeq-count [65] with the following parameters: --stranded yes –
mode union –type exon. These options summarise unambiguous read counts, on the sense 
strand, over entire gene units using all exons. Genes differentially expressed upon 
doxorubicin treatment in wt ES cells were identified using the Bioconductor package DESeq 
[66]. Genes with adjusted p-value < 0.05 and fold change ≥ 2.5 were identified as 
differentially expressed. Genes with a base Mean count < 200 (empirically determined) were 
removed from the list as they correspond to genes weakly expressed in both conditions. The 
corresponding differential expression heatmap (Figure 2A) was generated using Java 
Treeview [67]. A normalised count table was used to determine expression values (Figure 
S2G) and identify the 2500 most active genes in mouse ES cells (Figure 4) by correcting wt 
raw read counts for gene length. Average profile plots of sense and antisense transcription 
(Figure 5C-F) were generated in an identical manner to ChIP-Seq occupancy plots (see 
below) using normalised bigwig files for each strand (based on direction of paired end 
alignment). 
Average profile and heatmap analysis of ChIP-seq Occupancy 
All read depths were normalised to the total number of uniquely mapped reads in each 
experiment. ChIP-seq density was determined by calculating the average number of hits per 
base in 100 bp windows with a 20 bp slide using normalised bigwig files over a 6 kb interval 
centred on the TSS (for promoters) or a 3 kb interval over the centre of each peak (for non-
promoter regions) using custom Perl and R scripts interfaced with the Galaxy server [68,69], 
which are available upon request. Average profiles were generated by plotting the median 
value in each window for each sample. For heat maps, the sliding window file obtained from 
wt ES cells was subjected to k-means clustering using Cluster 3.0 [70]. Results from 
clustering were used to rank sliding windows files for all other samples accordingly. 
Clustered heatmaps were generated using Java Treeview. 
RNA extraction and RT-qPCR 
Cells were lysed in TRI reagent (Sigma). RNA was then extracted with chloroform, 
precipitated with isopropanol and DNAse treated (DNA-free, Ambion). 2 μg total RNA was 
used per reverse transcription reaction. RNA was denatured in the presence of 2 μg of 
random hexamers (Invitrogen) for 5 min at 75°C, and reverse transcribed in a final volume of 
40 μl with 200U of SuperScript II (Invitrogen) at 42°C overnight followed by heat 
inactivation at 70°C for 15 min. Synthesized complementary DNAs were diluted in 300 μl of 
water and stored at −20°C until used. 
Absolute quantification experiments were performed essentially as described in [39]. Briefly, 
5.10
5
 cells were lysed in 1 ml TRI reagent (Sigma) and 1 μl of a 1:20 dilution of ERCC 
Spike-in Mix#1 (Life technologies) was added to each sample. After RNA extraction and 
reverse transcription, cDNAs were analysed by RT-qPCR. Transcript abundance were 
normalised to ERCC-00074 spike-in standard. ERCC-00096 and ERCC-00130 were also 
used as secondary controls. 
Protein extraction and Western blotting 
Cells were lysed in RIPA buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1% 
Sodium deoxycholate) plus protease inhibitors and sonicated with a Bioruptor (Diagenode) 
for 10 cycles (30 seconds each cycle). Whole cell lysate were subjected to SDS-PAGE and 
transferred on nitrocellulose. 
Antibodies 
All antibodies are listed in Additional file 14. 
Oligonucleotides 
Oligonucleotides used for ChIP-qPCR, RT-qPCR and splicing analysis are listed in 
Additional file 15. 
Data access 
High throughput sequencing data (ChIP-Seq and RNA-Seq) have been deposited in the Gene 
Expression Omnibus (GEO) under the accession number GSE53492. 
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